|July 2006 · Vol. 18, No. 7
The HPV vaccine: A good start
FDA approval is an exciting first step. But 4 additional factors will determine the vaccine’s ultimate success
The ACIP recommendation strongly influences standard of practice, which strongly influences potential for public funding and insurance coverage
Last month the Food and Drug Administration approved the first vaccine (Gardisil) to prevent infection with specific types of human papillomavirus (HPV). The approval is the culmination of 2 decades of work in a variety of disciplines that have clearly demonstrated that infection with specific types of high-risk HPV is required for the development of cervical cancer—and that the development of HPV-associated disease can be prevented through vaccination.